LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.
The respiratory drug discovery firm said the second part of the phase two clinical trial will look to study the efficacy and safety of SNG001 in up to 120 patients with COPD.
This was after the first part of the phase two trial had successfully assessed the safety and antiviral biomarker activity of SNG001 in COPD patients.
"Cold and flu respiratory viruses cause approximately 50% of COPD exacerbations and are the second most common cause of unplanned hospital admission in England, presenting a significant health risk and economic burden", Synairgen Chief Executive Officer Richard Marsden said.
"With no effective broad spectrum antiviral treatment on the market, we believe treating COPD patients with our wholly-owned product, SNG001, has the potential to enhance greatly the patient's defences against viral infection, reduce exacerbations, increase quality of life and reduce hospitalisations," Marsden added. "Commencement of part two of this phase two trial in advance of the winter virus season is clearly another key milestone for Synairgen."
Shares in Synairgen were 1.5% lower at 16.50 pence on Monday.
Synairgen (SNG)